To hear about similar clinical trials, please enter your email below
Trial Title:
Study on the Staging and Prognosis Model of Bladder Cancer
NCT ID:
NCT06565923
Condition:
Bladder Cancer
Conditions: Official terms:
Urinary Bladder Neoplasms
Conditions: Keywords:
Multimodal omics features
artificial intelligence
staging and prognostic models
Bladder cancer
Study type:
Observational [Patient Registry]
Overall status:
Active, not recruiting
Study design:
Time perspective:
Prospective
Summary:
Firstly, we retrospectively gathered the patient information who compliant with the
criteria from 2012 to 2023, encompassing basic information, clinical information, along
with MRI images, blood/urine samples, and tissue samples, for conducting relevant
analyses of radiomics. Subsequently, based on artificial intelligence technology, deep
learning and machine learning models were established on the basis of MRI radiomics and
pathological histomics. Ultimately, the following research aims were accomplished: 1.
Primary research objective: To explore the role of artificial intelligence and multimodal
omics features in the staging and prognosis monitoring of bladder cancer. 2. Secondary
objective: To explore the correlations among radiomics, case histomics, and test omics.
Criteria for eligibility:
Study pop:
1. Patients with bladder cancer in preoperative examination; 2. Gender is not limited;
3. Age≥ 18 years old; 4. Be able to provide MRI images, pathological data and
laboratory examination data before the operation; 5. Agree to provide basic personal
clinical information and pathological and imaging data for scientific research use,
and sign the informed consent form; 6. Agree to provide monitoring results during
follow-up recurrence monitoring;
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
-
1. Patients with bladder cancer in preoperative examination; 2. Gender is not
limited; 3. Age≥ 18 years old; 4. Be able to provide MRI images, pathological
data and laboratory examination data before the operation; 5. Agree to provide
basic personal clinical information and pathological and imaging data for
scientific research use, and sign the informed consent form; 6. Agree to
provide monitoring results during follow-up recurrence monitoring;
Exclusion Criteria:
-
1. Incomplete clinicopathological data; 2. Combined with upper tract urothelial
carcinoma or previously diagnosed upper tract urothelial carcinoma; 3. Is
participating in the rest of the clinical studies; Unable to cooperate with the
relevant examinations of this project, and do not agree to sign the informed
consent form.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
The First Affiliated Hospital with Nanjing Medical University
Address:
City:
Nanjing
Country:
China
Start date:
March 18, 2024
Completion date:
July 18, 2025
Lead sponsor:
Agency:
The First Affiliated Hospital with Nanjing Medical University
Agency class:
Other
Collaborator:
Agency:
Suzhou Municipal Hospital
Agency class:
Other
Collaborator:
Agency:
Yixing People's Hospital
Agency class:
Other
Collaborator:
Agency:
Wuhan Union Hospital, China
Agency class:
Other
Collaborator:
Agency:
Huai an First People Hospital
Agency class:
Other
Collaborator:
Agency:
Jiangsu Province Hospital of Chinese Medicine
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Zhengzhou University
Agency class:
Other
Collaborator:
Agency:
The second affiliated hospital of Xuzhou medical university
Agency class:
Other
Source:
The First Affiliated Hospital with Nanjing Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06565923
